Rosehip trials for osteoarthritis
Two systematic reviews identified two RCTs that examined the clinical effectiveness of rosehip in osteoarthritis:
- In the first trial in the reviews, 100 people with hip and/or knee osteoarthritis were randomly assigned to receive either LitoZin tablets (5 g rosehip) or a placebo once a day for four months.
- The second trial involved 112 people with osteoarthritis in multiple sites. Participants were randomly assigned to receive either Hyben Vital tablets (5 g rosehip) or a placebo once a day for three months.
- In the first trial, rosehip significantly improved hip flexion when compared with the placebo, but it didn’t significantly improve the range of rotation of the hip and the degree of flexion of the knee.
- Significantly more participants in the active treatment group reported a reduction in pain compared with the placebo group.
- Of those given rosehip in the second trial, 66% reported a significant reduction in pain, compared to 36% of participants who received the placebo.
- The rosehip group also had a reduction in some disease-related symptoms (like morning stiffness) and a significant decline in painkiller use.
- In both trials, the active treatment was well tolerated with only minor gastrointestinal side-effects.
The treatment outcome of LitoZin (5 g rosehip) was compared with a placebo in 94 people with osteoarthritis.
- After three weeks of treatments, rosehip resulted in a significant reduction in pain scores and painkiller use compared to the placebo, but it didn’t significantly reduce stiffness and disability or improve the overall disease severity.
- After 15 weeks, participants who were given rosehip had a significant reduction in pain, stiffness, disability and painkiller use as well as significant improvement in overall disease severity compared to participants on the placebo.